Watchlists Portfolios Alerts Sign in Get started

SAB Biotherapeutics, Inc. SABS

Set alert

3.35 USD +0.12 +3.72%

At close · Oct 30

3.35 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid: 3.34 × 5
Ask: 3.36 × 2

3.11 Day range 3.37

2.49 52-week range 4.59

YTD: -10.43%
1 year: +11.30%

Open: 3.20
Prev close: 3.23
Mkt cap: 304.80M
Vol: 741.05K
Avg vol: 536.84K
EPS: -1.29
P/E: 0.00
Div yield: 0.00%

More statistics

Low: 3.11
High: 3.37
Forward P/E: -1.56
Beta: 0.64
Short ratio: 1.22
Inst. own: 34.25%
Dividend: 0.00
Ex-div date
Earnings: Aug 8, 2024
50-d avg: 3.29
200-d avg: 3.35
1y target: 12.40

Chart tools

Interval

1m 5m 15m 30m

Chart is warming up

The five-day price history for SABS has not been loaded yet. Try again in a moment.

Discussion (6)

VICKY HANUKA SABS Oct 19, 2023 3 years ago #1

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi

-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.